Analyst Reco. Rhythm Pharmaceuticals, Inc.

Equities

RYTM

US76243J1051

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-31 pm EDT			5-day change	1st Jan Change
35.68 ^USD	-2.73%		-2.94%	-22.38%

May. 22	Rhythm Pharmaceuticals' Imcivree Gains UK Recommendation for Treating Bardet-Biedl Syndrome	MT
May. 14	Transcript : Rhythm Pharmaceuticals, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 02:20 PM

Analyst Reco.

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

BofA Downgrades Rhythm Pharmaceuticals to Neutral From Buy, Adjusts Price Target to $42 From $49	May. 08	MT
Wells Fargo Trims Price Target on Rhythm Pharmaceuticals to $52 From $53, Maintains Overweight Rating	Apr. 18	MT
Rhythm Pharmaceuticals Insider Sold Shares Worth $735,600, According to a Recent SEC Filing	Mar. 22	MT
Rhythm Pharmaceuticals Insider Sold Shares Worth $707,005, According to a Recent SEC Filing	Mar. 22	MT
Rhythm Pharmaceuticals Insider Sold Shares Worth $608,498, According to a Recent SEC Filing	Mar. 20	MT
Rhythm Pharmaceuticals Insider Sold Shares Worth $627,520, According to a Recent SEC Filing	Mar. 20	MT
Rhythm Pharmaceuticals Insider Sold Shares Worth $608,498, According to a Recent SEC Filing	Mar. 20	MT
Rhythm Pharmaceuticals Insider Sold Shares Worth $608,498, According to a Recent SEC Filing	Mar. 20	MT
Rhythm Pharmaceuticals Insider Sold Shares Worth $608,498, According to a Recent SEC Filing	Mar. 20	MT
Goldman Sachs Raises Price Target on Rhythm Pharmaceuticals to $52 From $42, Maintains Buy Rating	Jan. 25	MT
Needham Raises Price Target on Rhythm Pharmaceuticals to $50 From $45, Maintains Buy Rating	Jan. 04	MT
Morgan Stanley Upgrades Rhythm Pharmaceuticals to Overweight From Equalweight, Raises Price Target to $55 From $29	Dec. 19	MT
Wells Fargo Raises Rhythm Pharmaceuticals Price Target to $53 From $48, Maintains Overweight Rating	Dec. 19	MT
Goldman Sachs Raises Price Target on Rhythm Pharmaceuticals to $42 From $38, Maintains Buy Rating	Dec. 07	MT
Needham Raises Rhythm Pharmaceuticals Price Target to $45 From $32, Maintains Buy Rating	Dec. 07	MT
Morgan Stanley Adjusts Rhythm Pharmaceuticals' Price Target to $29 From $28, Keeps Equalweight Rating	23-10-10	MT
BofA Securities Upgrades Rhythm Pharmaceuticals to Buy From Neutral, Adjusts Price Target to $27 From $22	23-08-02	MT
Goldman Sachs Raises Rhythm Pharmaceuticals' Price Target to $45 From $40, Maintains Buy Rating	23-03-02	MT
Canaccord Genuity Adjusts Price Target on Rhythm Pharmaceuticals to $56 From $52, Keeps Buy Rating	23-03-02	MT
Morgan Stanley Adjusts Price Target on Rhythm Pharmaceuticals to $28 From $26, Keeps Equalweight Rating	23-03-02	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Rhythm Pharmaceuticals, Inc.

Equities

RYTM

US76243J1051

Analyst Reco.

Filters